국소적으로 진행된 비소세포폐암의 치료성적
Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer

대한방사선종양학회지 2006년 24권 4호 p.237 ~ p.242

이희관(Lee Heui Kwan) - 전북대학교병원 방사선종양학과
권형철(Kwon Hyoung-Cheol) - 전북대학교병원 방사선종양학과
이선영(Lee Sun-Young) - 전북대학교병원 방사선종양학과
김정수(Kim Jung-Soo) - 전북대학교병원 방사선종양학과

Abstract

목 적: 국소적으로 진행된 비소세포성 폐암에서 예후영향인자를 찾기 위하여 근치적 방사선 치료에 대한 성적을
후향적으로 평가하였다.

대상 및 방법: 1991∼2002년에 걸쳐 본원에서 방사선치료를 받은 stage IIIB 비소세포성 폐암 환자 216명의 의무기
록을 후향적으로 분석하였다. 완전관해와 부분관해를 반응군(response group), 불변 및 진행성질환을 무반응군
(non-response group)으로 묶어 분류하였다.

결 과: 근치목적의 방사선치료를 시행한 총 140명의 환자 중 방사선단독치료를 받은 환자는 68명, 항암화학제와
병용요법을 시행한 환자는 72명이었다. 계획된 방사선치료가 완료된 것은 단독에서는 30예, 병용요법에서는 39예
였다. 중앙생존기간은 방사선 단독치료군에서는 4.6개월, 병용요법군에서는 9.9개월이었다. 1년, 2년 및 3년 생존율
이 방사선 단독치료군에서는 13.3%, 3.3%, 0%였으며, 항암화학제 병용요법군에서는 각각 35.9%, 20.5%, 15.4%였다
(p<0.001). 반응군에서 방사선 단독으로 치료한 환자는 중앙생존기간 7.2개월, 항암화학제 병용치료환자는 16.5개
월이었고, 무반응군에서 단독치료 환자는 4.4개월, 병용치료환자는 6.7개월이었다(p=0.001). 치료반응과 항암화학요
법의 병용이 전체생존율에 영향을 주었다(p<0.001). Grade 3 이상의 심한 합병증은 방사선 단독요법에서 2예
(6.7%), 항암화학 병용요법에서 7예(17.9%)였다.

결 론: Stage IIIB 비소세포성 폐암에서 방사선치료와 더불어 항암화학치료를 병용했을 때, 방사선단독요법에 비해
치료반응률과 생존율이 더 높았다.
Purpose: We evaluated retrospectively the outcome of locally advanced non-small cell lung cancer patients
treated with definitive radiotherapy to find out prognostic factros affecting survival.

Materials and Methods: 216 cases of stage IIIB non-small cell lung cancer were with treated radiotherapy at
our Hospital between 1991 to 2002 and reviewed retrospectively. Cases were classified by mode of treatment
and response to treatment. Patients showing complete response or partial response to treatment were included
in the “response group”, while those showing stable or progressive cancer were included in the “nonresponse
group”.

Results: 30 patients completed the planned radiotherapy treatments and 39 patients completed combined
treatments or chemoradiotherapy. Median survival was 4.6 months for patients treated with radiotherapy and 9.9
months for those undergoing combined radiotherapy and chemotherapy. Survival rates for the first year were
13.3% with radiotherapy and 35.9% with chemoradiotherapy. In the second year, 3.3% of the radiotherapy
patients survived and 20.5% of the patients receiving chemoradiotherapy survived. By the third year, 15.4% of
the patients receiving the combined treatments survived. None of the patients treated with radiotherapy alone
lived to the third year, however. Overall survival was significantly different between the radiotherapy patients and
the combined chemoradiotherapy patients (p<0.001). In the response group, median survival was 7.2 months
with radiotherapy and 16.5 months with combined therapy. In the non-response group, median survival was 4.4
months with radiotherapy and 6.7 months with combined treatments. Severe acute complications (grade 3)
occurred in 2 cases using radiotherapy, and in 7 cases using combined therapy .

Conclusion: When the patients with stage IIIB non-small cell lung cancer received chemoradiotherapy,
treatment response rate and overall survival was greater than with radiation alone.

키워드

비소세포성 폐암, 방사선치료, 생존율
Non-small cell lung carcinoma, Radiotherapy, Survival
원문 및 링크아웃 정보
등재저널 정보
학술진흥재단(KCI) KoreaMed 대한의학회 회원 
주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
When the patients with stage IIIB non-small cell lung cancer received chemoradiotherapy, treatment response rate and overall survival was greater than with radiation alone.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
KCD코드
ICD 03
건강보험코드